01815nas a2200205   4500008004100000022001400041245005100055210005100106260000800157300001200165490000700177520118300184653002001367653002101387653002801408653002601436653003401462100002701496856008601523       2021                        eng d  a0301-120800aOral insulin delivery using artificial peptide0 aOral insulin delivery using artificial peptide  cOCT  a408-4150 v583 aThe daily multiple insulin injection is the line of treatment for diabetes mellitus. As the oral insulin delivery mimics, the physiology of endogenous insulin secreted by pancreas. Recently, the search for suitable carrier to develop oral insulin delivery has been intensified. However, the carrier toxicity and very less bioavailability of insulin remains the major problem in the development of oral insulin delivery. Preparation of a non-covalent insulin-peptide complex using different peptide made of 16 to 20 L-amino acids studied to overcome the problem. The in vitro testing of insulin-peptide complex showed significant stability against the proteolytic enzyme. Whereas, in in vivo testing, the presence of 10-41% insulin in blood plasma observed after 30 to 60 min oral feeding of insulin-peptide complex. Results indicated that the peptide which showed moderate protection against pepsin and minor protection against trypsin and chymotrypsin has an important role in enhancing oral insulin bioavailability. However, the peptide which showed higher protection against trypsin and no protection against pepsin could not achieve significant oral insulin bioavailability.10aBioavailability10aCarrier toxicity10aInsulin-peptide complex10aOral insulin delivery10aProteolytic enzyme resistance1 aAdikane, Harshavardhan  uhttps://library.ncl.res.in/content/oral-insulin-delivery-using-artificial-peptide02742nas a2200241   4500008004100000022001400041245010300055210006900158260000800227300001200235490000700247520195100254653001202205653002002217653001402237653001802251653002102269100002302290700002102313700002402334700001902358856012302377       2026                        eng d  a0724-874100aNovel cocrystal of quercetagetin: in vitro and in vivo insights into biopharmaceutical performance0 aNovel cocrystal of quercetagetin in vitro and in vivo insights i  cMAR  a927-9390 v433 a<p>
	Purpose Quercetagetin (QTGN) is a naturally occurring flavonol predominantly sourced from marigold flowers and possesses notable therapeutic potential, including antidiabetic, anticancer, antioxidant, anti-inflammatory, and antiviral properties. However, poor aqueous solubility and in turn bioavailability restrict therapeutic utility of QTGN. Crystal engineering is one of the approaches proven to be fruitful in resolving the solubility issues of many active pharmaceutical ingredients (APIs). Method In the present work, a cocrystal of QTGN using betaine (BET) as coformer viz. Quercetagetin &amp; sdot;betaine &amp; sdot;ethanol (QTGN &amp; sdot;BET &amp; sdot;EtOH) was synthesized using the solvent evaporation method. It was further characterized using Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Thermogravimetric analysis (TGA), Powder X-ray diffraction (PXRD), and single crystal XRD (SCXRD). Result FTIR studies confirmed hydrogen bonding between QTGN and BET. PXRD studies showed formation of new crystalline phase. The prepared cocrystal had stoichiometric ratio of 1:1:1 between QTGN, BET, and ethanol forming cocrystal ethanolate and shared robust hydroxyl &amp; ctdot;carboxylate supramolecular synthon as confirmed by TGA and SCXRD, respectively. Equilibrium solubility study and in vitro dissolution study showed a significant improvement (p &lt; 0.0001) in aqueous solubility of QTGN upon its cocrystallization with BET. Furthermore, in vivo pharmacokinetic study revealed a 1.28-fold increase in bioavailability of QTGN when formulated as cocrystal solvate. The prepared cocrystal was found to be stable over a period of six months at 40 degrees C and 75% RH when analyzed using PXRD studies. Conclusion The current work represents a frontier in pharmaceutical formulation, providing a means to fully harness the therapeutic potential of QTGN using cocrystal approach.</p>
10abetaine10aBioavailability10acocrystal10aquercetagetin10aUSP apparatus IV1 aSuryawanshi, Smita1 aShaligram, Parth1 aGonnade, Rajesh, G.1 aPatil, Sharvil  uhttps://library.ncl.res.in/content/novel-cocrystal-quercetagetin-vitro-and-vivo-insights-biopharmaceutical-performance